## Francesco Dotta

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9549839/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Krebs von den Lungen-6 as Disease Severity Marker for COVID-19 Patients: Analytical Verification and Quality Assessment of the Tosoh AIA-360 Compared to Lumipulse G600II. International Journal of Environmental Research and Public Health, 2022, 19, 2176.	2.6	4
2	Circulating microRNAs as clinically useful biomarkers for Type 2 Diabetes Mellitus: miRNomics from bench to bedside. Translational Research, 2022, 247, 137-157.	5.0	10
3	Serum Proteomic Profile of Asthmatic Patients after Six Months of Benralizumab and Mepolizumab Treatment. Biomedicines, 2022, 10, 761.	3.2	2
4	Increased Expression of Viral Sensor MDA5 in Pancreatic Islets and in Hormone-Negative Endocrine Cells in Recent Onset Type 1 Diabetic Donors. Frontiers in Immunology, 2022, 13, 833141.	4.8	9
5	Identification and Validation of miR-222-3p and miR-409-3p as Plasma Biomarkers in Gestational Diabetes Mellitus Sharing Validated Target Genes Involved in Metabolic Homeostasis. International Journal of Molecular Sciences, 2022, 23, 4276.	4.1	18
6	NF-κB-inducing kinase (NIK) is activated in pancreatic β-cells but does not contribute to the development of diabetes. Cell Death and Disease, 2022, 13, 476.	6.3	4
7	Crosstalk between MicroRNA and Oxidative Stress in Physiology and Pathology 2.0. International Journal of Molecular Sciences, 2022, 23, 6831.	4.1	6
8	The Landscape of microRNAs in βCell: Between Phenotype Maintenance and Protection. International Journal of Molecular Sciences, 2021, 22, 803.	4.1	11
9	Regulatory T cell monitoring in severe eosinophilic asthma patients treated with mepolizumab. Scandinavian Journal of Immunology, 2021, 94, e13031.	2.7	12
10	Prognostic bioindicators in severe COVID-19 patients. Cytokine, 2021, 141, 155455.	3.2	30
11	Extracellular Vesicles in Immune System Regulation and Type 1 Diabetes: Cell-to-Cell Communication Mediators, Disease Biomarkers, and Promising Therapeutic Tools. Frontiers in Immunology, 2021, 12, 682948.	4.8	23
12	Non-Coding RNAs: Novel Players in Insulin Resistance and Related Diseases. International Journal of Molecular Sciences, 2021, 22, 7716.	4.1	15
13	Circulating microRNAs Signature for Predicting Response to GLP1-RA Therapy in Type 2 Diabetic Patients: A Pilot Study. International Journal of Molecular Sciences, 2021, 22, 9454.	4.1	12
14	Immunoregulated insulitis and slow-progressing type 1 diabetes after duodenopancreatectomy. Diabetologia, 2021, 64, 2731-2740.	6.3	4
15	Protocol to analyze circulating small non-coding RNAs by high-throughput RNA sequencing from human plasma samples. STAR Protocols, 2021, 2, 100606.	1.2	7
16	CD8+ T cells variably recognize native versus citrullinated GRP78 epitopes in type 1 diabetes. Diabetes, 2021, 70, db210259.	0.6	11
17	miR-409-3p is reduced in plasma and islet immune infiltrates of NOD diabetic mice and is differentially expressed in people with type 1 diabetes. Diabetologia, 2020, 63, 124-136.	6.3	23
18	From immunohistological to anatomical alterations of human pancreas in type 1 diabetes: New concepts on the stage. Diabetes/Metabolism Research and Reviews, 2020, 36, e3264.	4.0	20

#	Article	IF	CITATIONS
19	MicroRNA Expression in the Aqueous Humor of Patients with Diabetic Macular Edema. International Journal of Molecular Sciences, 2020, 21, 7328.	4.1	14
20	Pancreatic Alpha-Cells Contribute Together With Beta-Cells to CXCL10 Expression in Type 1 Diabetes. Frontiers in Endocrinology, 2020, 11, 630.	3.5	17
21	SARS-CoV-2 Receptor Angiotensin I-Converting Enzyme Type 2 (ACE2) Is Expressed in Human Pancreatic β-Cells and in the Human Pancreas Microvasculature. Frontiers in Endocrinology, 2020, 11, 596898.	3.5	144
22	Prevention and treatment of autoimmune diseases with plant virus nanoparticles. Science Advances, 2020, 6, eaaz0295.	10.3	22
23	Intestinal Delivery of Proinsulin and IL-10 via Lactococcus lactis Combined With Low-Dose Anti-CD3 Restores Tolerance Outside the Window of Acute Type 1 Diabetes Diagnosis. Frontiers in Immunology, 2020, 11, 1103.	4.8	19
24	Crosstalk between MicroRNA and Oxidative Stress in Physiology and Pathology. International Journal of Molecular Sciences, 2020, 21, 1270.	4.1	9
25	Dual energy CT in gland tumors: a comprehensive narrative review and differential diagnosis. Gland Surgery, 2020, 9, 2269-2282.	1.1	10
26	1795-P: Proinsulin-Insulin Pancreatic Islets In-situ Expression Mirrors Metabolic Defects Observed in Type 2 Diabetic and Glucose Intolerant Living Donors. Diabetes, 2020, 69, 1795-P.	0.6	0
27	Fostering improved human islet research: a European perspective. Diabetologia, 2019, 62, 1514-1516.	6.3	13
28	Molecular Dysfunction and Phenotypic Derangement in Diabetic Cardiomyopathy. International Journal of Molecular Sciences, 2019, 20, 3264.	4.1	93
29	Is resistant hypertension an independent predictor of all-cause mortality in individuals with type 2 diabetes? A prospective cohort study. BMC Medicine, 2019, 17, 83.	5.5	9
30	Targeting microRNAs as a Therapeutic Strategy to Reduce Oxidative Stress in Diabetes. International Journal of Molecular Sciences, 2019, 20, 6358.	4.1	29
31	Ten years of experience with DPP-4 inhibitors for the treatment of type 2 diabetes mellitus. Acta Diabetologica, 2019, 56, 605-617.	2.5	50
32	Lymphocyte-Derived Exosomal MicroRNAs Promote Pancreatic β Cell Death and May Contribute to Type 1 Diabetes Development. Cell Metabolism, 2019, 29, 348-361.e6.	16.2	200
33	Islet-reactive CD8 <sup>+</sup> T cell frequencies in the pancreas, but not in blood, distinguish type 1 diabetic patients from healthy donors. Science Immunology, 2018, 3, .	11.9	171
34	G-protein-coupled receptors (GPCRs) in the treatment of diabetes: Current view and future perspectives. Best Practice and Research in Clinical Endocrinology and Metabolism, 2018, 32, 201-213.	4.7	12
35	Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial. Diabetes Care, 2018, 41, 258-266.	8.6	350
36	Rome as a walkable city for reduce the impact of the Obesity,T2DM and CDV risks. European Journal of Public Health, 2018, 28, .	0.3	0

#	Article	IF	CITATIONS
37	Urban health in Italy: health outcomes and sustainable living. European Journal of Public Health, 2018, 28, .	0.3	0
38	MicroRNAs as Regulators of Insulin Signaling: Research Updates and Potential Therapeutic Perspectives in Type 2 Diabetes. International Journal of Molecular Sciences, 2018, 19, 3705.	4.1	77
39	Acute on chronic limb ischemia: From surgical embolectomy and thrombolysis to endovascular options. Seminars in Vascular Surgery, 2018, 31, 66-75.	2.8	21
40	Fighting diabetic foot ulcers—The diabetologist: A king maker of the fight. Seminars in Vascular Surgery, 2018, 31, 49-55.	2.8	5
41	Serum Levels of miR-148a and miR-21-5p Are Increased in Type 1 Diabetic Patients and Correlated with Markers of Bone Strength and Metabolism. Non-coding RNA, 2018, 4, 37.	2.6	39
42	Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet, The, 2018, 392, 1519-1529.	13.7	1,179
43	Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes: The DEPICT-1 52-Week Study. Diabetes Care, 2018, 41, 2552-2559.	8.6	177
44	MicroRNAs: markers of $\hat{i}^2$ -cell stress and autoimmunity. Current Opinion in Endocrinology, Diabetes and Obesity, 2018, 25, 237-245.	2.3	19
45	Circulating MicroRNAs as Biomarkers of Gestational Diabetes Mellitus: Updates and Perspectives. International Journal of Endocrinology, 2018, 2018, 1-11.	1.5	49
46	Circulating MicroRNAs in Elderly Type 2 Diabetic Patients. International Journal of Endocrinology, 2018, 2018, 1-11.	1.5	32
47	Conventional and Neo-antigenic Peptides Presented by β Cells Are Targeted by Circulating NaÃ⁻ve CD8+ T Cells in Type 1 Diabetic and Healthy Donors. Cell Metabolism, 2018, 28, 946-960.e6.	16.2	177
48	Unexpected subcellular distribution of a specific isoform of the Coxsackie and adenovirus receptor, CAR-SIV, in human pancreatic beta cells. Diabetologia, 2018, 61, 2344-2355.	6.3	60
49	MicroRNA Expression Analysis of In Vitro Dedifferentiated Human Pancreatic Islet Cells Reveals the Activation of the Pluripotency-Related MicroRNA Cluster miR-302s. International Journal of Molecular Sciences, 2018, 19, 1170.	4.1	14
50	Putative endothelial progenitor cells predict long-term mortality in type-2 diabetes. Endocrine, 2018, 62, 263-266.	2.3	6
51	Abnormal neutrophil signature in the blood and pancreas of presymptomatic and symptomatic type 1 diabetes. JCI Insight, 2018, 3, .	5.0	85
52	Urban diabetes: the case of the metropolitan area of Rome. European Journal of Public Health, 2018, 28,	0.3	0
53	Circulating microRNAs and diabetes mellitus: a novel tool for disease prediction, diagnosis, and staging?. Journal of Endocrinological Investigation, 2017, 40, 591-610.	3.3	72
54	Dapagliflozin modulates glucagon secretion in an SGLT2-independent manner in murine alpha cells. Diabetes and Metabolism, 2017, 43, 512-520.	2.9	51

#	Article	IF	CITATIONS
55	MicroRNA expression profiles of human iPSCs differentiation into insulin-producing cells. Acta Diabetologica, 2017, 54, 265-281.	2.5	36
56	Rationale and design of the DARWIN-T2D (DApagliflozin Real World evIdeNce in Type 2 Diabetes). Nutrition, Metabolism and Cardiovascular Diseases, 2017, 27, 1089-1097.	2.6	26
57	Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes and Endocrinology,the, 2017, 5, 864-876.	11.4	244
58	Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial. Lancet Diabetes and Endocrinology,the, 2017, 5, 887-897.	11.4	231
59	Regulatory T-cells from pancreatic lymphnodes of patients with type-1 diabetes express increased levels of microRNA miR-125a-5p that limits CCR2 expression. Scientific Reports, 2017, 7, 6897.	3.3	53
60	Reversal of Diabetes in NOD Mice by Clinical-Grade Proinsulin and IL-10–Secreting Lactococcus lactis in Combination With Low-Dose Anti-CD3 Depends on the Induction of Foxp3-Positive T Cells. Diabetes, 2017, 66, 448-459.	0.6	57
61	MicroRNAs miR-23a-3p, miR-23b-3p, and miR-149-5p Regulate the Expression of Proapoptotic BH3-Only Proteins DP5 and PUMA in Human Pancreatic β-Cells. Diabetes, 2017, 66, 100-112.	0.6	87
62	Circulating microRNA (miRNA) Expression Profiling in Plasma of Patients with Gestational Diabetes Mellitus Reveals Upregulation of miRNA miR-330-3p. Frontiers in Endocrinology, 2017, 8, 345.	3.5	65
63	The map of diabetes and its determinants within the metropolitan area of Rome. European Journal of Public Health, 2017, 27, .	0.3	0
64	Efficacy and safety of once-weekly semaglutide vs exenatide ER after 56 Weeks in subjects with type 2 diabetes (SUSTAIN 3). Diabetes Research and Clinical Practice, 2016, 120, S51.	2.8	9
65	Efficacy and Safety of Once-Weekly Semaglutide vs. Exenatide ER after 56 Weeks in Subjects with Type 2 Diabetes (SUSTAIN 3). Canadian Journal of Diabetes, 2016, 40, S41.	0.8	3
66	Relative sensitivity of immunohistochemistry, multiple reaction monitoring mass spectrometry, in situ hybridization and PCR to detect Coxsackievirus B1 in A549 cells. Journal of Clinical Virology, 2016, 77, 21-28.	3.1	23
67	Erectile dysfunction and diabetes: Association with the impairment of lipid metabolism and oxidative stress. Clinical Biochemistry, 2016, 49, 70-78.	1.9	14
68	Long-term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study. Cardiovascular Diabetology, 2015, 14, 116.	6.8	39
69	MicroRNAs: Novel Players in the Dialogue between Pancreatic Islets and Immune System in Autoimmune Diabetes. BioMed Research International, 2015, 2015, 1-11.	1.9	50
70	Tyrosine Phosphatase–Related Islet Antigen 2(256–760) Autoantibodies, the Only Marker of Islet Autoimmunity That Increases by Increasing the Degree of BMI in Obese Subjects With Type 2 Diabetes. Diabetes Care, 2015, 38, 513-520.	8.6	29
71	The social burden of hypoglycemia in the elderly. Acta Diabetologica, 2015, 52, 677-685.	2.5	40
72	Human induced pluripotent stem cells differentiate into insulin-producing cells able to engraft in vivo. Acta Diabetologica, 2015, 52, 1025-1035.	2.5	33

#	Article	IF	CITATIONS
73	Treatment escalation options for patients with type 2 diabetes after failure of exenatide twice daily or glimepiride added to metformin: results from the prospective <scp>E</scp> uropean <scp>E</scp> xenatide ( <scp>EUREXA</scp> ) study. Diabetes, Obesity and Metabolism, 2015, 17, 689-698.	4.4	4
74	Towards an Earlier and Timely Diagnosis of Type 1 Diabetes: Is it Time to Change Criteria to Define Disease Onset?. Current Diabetes Reports, 2015, 15, 115.	4.2	11
75	Mast cells infiltrate pancreatic islets in human type 1 diabetes. Diabetologia, 2015, 58, 2554-2562.	6.3	46
76	MicroRNA-124a is hyperexpressed in type 2 diabetic human pancreatic islets and negatively regulates insulin secretion. Acta Diabetologica, 2015, 52, 523-530.	2.5	127
77	Enteroviral Infections and Development of Type 1 Diabetes: The Brothers Karamazov Within the CVBs. Diabetes, 2014, 63, 384-386.	0.6	13
78	Dietary Supplementation With High Doses of Regular Vitamin D3 Safely Reduces Diabetes Incidence in NOD Mice When Given Early and Long Term. Diabetes, 2014, 63, 2026-2036.	0.6	66
79	Photodynamic topical antimicrobial therapy for infected foot ulcers in patients with diabetes: a randomized, double-blind, placebo-controlled study—the D.A.N.T.E (Diabetic ulcer Antimicrobial New) Tj ETQq	l 1 <b>0.5</b> 7843	144gBT /Ove
80	IL-17A increases the expression of proinflammatory chemokines in human pancreatic islets. Diabetologia, 2014, 57, 502-511.	6.3	47
81	Circulating miRNA95 and miRNA190 Are Sensitive Markers for the Differential Diagnosis of Thyroid Nodules in a Caucasian Population. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 4190-4198.	3.6	53
82	Oral Delivery of Glutamic Acid Decarboxylase (GAD)-65 and IL10 by <i>Lactococcus lactis</i> Reverses Diabetes in Recent-Onset NOD Mice. Diabetes, 2014, 63, 2876-2887.	0.6	129
83	Long-standing type 1 diabetes: patients with adult-onset develop celiac-specific immunoreactivity more frequently than patients with childhood-onset diabetes, in a disease duration-dependent manner. Acta Diabetologica, 2014, 51, 675-678.	2.5	9
84	Coxsackieviruses and Insulitis. , 2013, , 157-166.		0
85	The Year in Immune Intervention for Type 1 Diabetes. Diabetes Technology and Therapeutics, 2013, 15, S-88-S-95.	4.4	8
86	Reduction of Circulating Neutrophils Precedes and Accompanies Type 1 Diabetes. Diabetes, 2013, 62, 2072-2077.	0.6	177
87	Beyond Glycemic Control in Diabetes Mellitus: Effects of Incretin-Based Therapies on Bone Metabolism. Frontiers in Endocrinology, 2013, 4, 73.	3.5	36
88	Endocrine Actions of Osteocalcin. International Journal of Endocrinology, 2013, 2013, 1-10.	1.5	105
89	The case for virus-induced type 1 diabetes. Current Opinion in Endocrinology, Diabetes and Obesity, 2013, 20, 292-298.	2.3	25
90	Viral Infections and Diabetes. Advances in Experimental Medicine and Biology, 2013, 771, 252-271.	1.6	27

#	Article	IF	CITATIONS
91	Incretin hormones and beta-cell mass expansion: what we know and what is missing?. Archives of Physiology and Biochemistry, 2013, 119, 161-169.	2.1	11
92	MicroRNA profiling in sera of patients with type 2 diabetes mellitus reveals an upregulation of miR-31 expression in subjects with microvascular complications. Journal of Biomedical Science and Engineering, 2013, 06, 58-64.	0.4	18
93	Demonstration of islet-autoreactive CD8 T cells in insulitic lesions from recent onset and long-term type 1 diabetes patients. Journal of Experimental Medicine, 2012, 209, 51-60.	8.5	572
94	Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial. Lancet, The, 2012, 379, 2270-2278.	13.7	138
95	A local glucagon-like peptide 1 (GLP-1) system in human pancreatic islets. Diabetologia, 2012, 55, 3262-3272.	6.3	208
96	Circulating Sclerostin Levels and Bone Turnover in Type 1 and Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 1737-1744.	3.6	222
97	In vitro effects of mycophenolic acid on survival, function, and gene expression of pancreatic beta-cells. Acta Diabetologica, 2012, 49, 123-131.	2.5	7
98	Combination therapy with metformin plus vildagliptin in type 2 diabetes mellitus. Expert Opinion on Pharmacotherapy, 2012, 13, 1377-1384.	1.8	14
99	Immunology in the clinic review series; focus on type 1 diabetes and viruses: how viral infections modulate beta cell function. Clinical and Experimental Immunology, 2012, 168, 24-29.	2.6	31
100	In Type 1 Diabetes Immunocompetent Cells are Defective in ILâ€16 Secretion. Scandinavian Journal of Immunology, 2012, 75, 127-128.	2.7	2
101	Reversal of autoimmune diabetes by restoration of antigen-specific tolerance using genetically modified Lactococcus lactis in mice. Journal of Clinical Investigation, 2012, 122, 1717-1725.	8.2	168
102	Detection of four diabetes specific autoantibodies in a single radioimmunoassay: an innovative high-throughput approach for autoimmune diabetes screening. Clinical and Experimental Immunology, 2011, 166, 317-324.	2.6	26
103	MicroRNAs as New Tools for Exploring Type 1 Diabetes: Relevance for Immunomodulation and Transplantation Therapy. Transplantation Proceedings, 2011, 43, 330-332.	0.6	12
104	Measuring adrenal autoantibody response: Interlaboratory concordance in the first international serum exchange for the determination of 21-hydroxylase autoantibodies. Clinical Immunology, 2011, 140, 291-299.	3.2	27
105	Innate immunity and the pathogenesis of type 1 diabetes. Seminars in Immunopathology, 2011, 33, 57-66.	6.1	40
106	Delta ellâ€specific expression of hedgehog pathway Ptch1 receptor in murine and human endocrine pancreas. Diabetes/Metabolism Research and Reviews, 2011, 27, 755-760.	4.0	7
107	Increased expression of microRNA miRâ€326 in type 1 diabetic patients with ongoing islet autoimmunity. Diabetes/Metabolism Research and Reviews, 2011, 27, 862-866.	4.0	116
108	Comment on: Meagher et al. Neutralization of Interleukin-16 Protects Nonobese Diabetic Mice From Autoimmune Type 1 Diabetes by a CCL4-Dependent Mechanism. Diabetes 2010;59:2862-2871. Diabetes, 2011, 60, e12-e12.	0.6	3

#	Article	IF	CITATIONS
109	Histopathology and ex vivo insulin secretion of pancreatic islets in gestational diabetes: A case report. Islets, 2011, 3, 231-233.	1.8	8
110	Palmitate induces a pro-inflammatory response in human pancreatic islets that mimics CCL2 expression by beta cells in type 2 diabetes. Diabetologia, 2010, 53, 1395-1405.	6.3	200
111	Virus Infections: Lessons from Pancreas Histology. Current Diabetes Reports, 2010, 10, 357-361.	4.2	13
112	Islet inflammation and CXCL10 in recent-onset type 1 diabetes. Clinical and Experimental Immunology, 2010, 159, 338-343.	2.6	161
113	Serum transforming growth factor $\hat{l}^21$ during diabetes development in non-obese diabetic mice and humans. Clinical and Experimental Immunology, 2010, 162, 407-414.	2.6	10
114	Changes in body composition after 9 months of treatment with exenatide twice daily versus glimepiride: comment letter on Jendle et al Diabetes, Obesity and Metabolism, 2010, 12, 1127-1128.	4.4	8
115	Cytotoxic T lymphocyte antigen-4 Ala17 polymorphism is a genetic marker of autoimmune adrenal insufficiency: Italian association study and meta-analysis of European studies. European Journal of Endocrinology, 2010, 162, 361-369.	3.7	35
116	Mechanisms of impaired bone strength in type 1 and 2 diabetes. Nutrition, Metabolism and Cardiovascular Diseases, 2010, 20, 683-690.	2.6	92
117	GAD and IA-2 autoantibody detection in type 1 diabetic patient saliva. Clinical Immunology, 2009, 131, 271-276.	3.2	4
118	Diagnosis and approach to posttransplant diabetes. Current Diabetes Reports, 2009, 9, 317-323.	4.2	6
119	Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin. Diabetes, Obesity and Metabolism, 2009, 11, 589-595.	4.4	100
120	Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatmentâ€naive patients with type 2 diabetes mellitus. Diabetes, Obesity and Metabolism, 2009, 11, 506-515.	4.4	164
121	Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24â€week, randomized, doubleâ€blind study*. Diabetes, Obesity and Metabolism, 2008, 10, 82-90.	4.4	157
122	Generalised reduction of putative endothelial progenitors and CXCR4-positive peripheral blood cells in type 2 diabetes. Diabetologia, 2008, 51, 1296-1305.	6.3	111
123	Can NK cells be a therapeutic target in human type 1 diabetes?. European Journal of Immunology, 2008, 38, 2961-2963.	2.9	20
124	Hedgehog Signaling during Expansion of Human Pancreatic Isletâ€Đerived Precursors. Annals of the New York Academy of Sciences, 2008, 1150, 43-45.	3.8	2
125	An overview of pancreatic beta-cell defects in human type 2 diabetes: Implications for treatment. Regulatory Peptides, 2008, 146, 4-11.	1.9	99
126	Analysis of Posttransplant Diabetes Mellitus Prevalence in a Population of Kidney Transplant Recipients. Transplantation Proceedings, 2008, 40, 1888-1890.	0.6	34

#	Article	IF	CITATIONS
127	Incretine e funzione insulare: fisiopatologia. L Endocrinologo, 2008, 9, 155-162.	0.0	0
128	Thyrotoxic periodic paralysis in an Italian man: clinical manifestation and genetic analysis. Annals of Clinical Biochemistry, 2008, 45, 218-220.	1.6	5
129	Identification of Tyrosine Phosphatase 2(256–760) Construct as a New, Sensitive Marker for the Detection of Islet Autoimmunity in Type 2 Diabetic Patients. Diabetes, 2008, 57, 1276-1283.	0.6	53
130	POST TRANSPLANTATION DIABETES MELLITUS: ROLE OF INSULIN-RESISTANCE AND PRO-INFLAMMATORY CYTOKINES IN FIRST YEAR POST-TRANSPLANT. Transplantation, 2008, 86, 275.	1.0	0
131	Coxsackie B4 virus infection of Î <sup>2</sup> cells and natural killer cell insulitis in recent-onset type 1 diabetic patients. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 5115-5120.	7.1	521
132	High Titer of Autoantibodies to GAD Identifies a Specific Phenotype of Adult-Onset Autoimmune Diabetes. Diabetes Care, 2007, 30, 932-938.	8.6	206
133	Type VII collagen in Alport syndrome. Nephrology Dialysis Transplantation, 2007, 22, 3501-3507.	0.7	2
134	Generation and expansion of multipotent mesenchymal progenitor cells from cultured human pancreatic islets. Cell Death and Differentiation, 2007, 14, 1860-1871.	11.2	89
135	Evidence of a selective epitope loss of anti-transglutaminase immunoreactivity in gluten-free diet celiac sera: A new tool to distinguish disease-specific immunoreactivities. Clinical Immunology, 2006, 121, 40-46.	3.2	4
136	Impaired Caspase-3 Expression by Peripheral T Cells in Chronic Autoimmune Thyroiditis and in Autoimmune Polyendocrine Syndrome-2. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 5064-5068.	3.6	26
137	Guidelines for the treatment and management of newâ€onset diabetes after transplantation <sup>1</sup> . Clinical Transplantation, 2005, 19, 291-298.	1.6	228
138	Oral probiotic administration induces interleukin-10 production and prevents spontaneous autoimmune diabetes in the non-obese diabetic mouse. Diabetologia, 2005, 48, 1565-1575.	6.3	309
139	Latent autoimmune diabetes in adults (LADA) should be less latent. Diabetologia, 2005, 48, 2206-2212.	6.3	294
140	Defective lymphocyte caspase-3 expression in type 1 diabetes mellitus. European Journal of Endocrinology, 2005, 152, 119-125.	3.7	22
141	Suppressor of cytokine signaling gene expression in human pancreatic islets: modulation by cytokines. European Journal of Endocrinology, 2005, 152, 485-489.	3.7	31
142	The acquisition of an insulin-secreting phenotype by HGF-treated rat pancreatic ductal cells (ARIP) is associated with the development of susceptibility to cytokine-induced apoptosis. Journal of Molecular Endocrinology, 2005, 34, 367-376.	2.5	10
143	CD4+CD25high regulatory T cells in human autoimmune diabetes. Journal of Autoimmunity, 2005, 24, 55-62.	6.5	181
144	IA-2 combined epitope assay: A new, highly sensitive approach to evaluate IA-2 humoral autoimmunity in type 1 diabetes. Clinical Immunology, 2005, 115, 260-267.	3.2	16

#	Article	IF	CITATIONS
145	Type 1 diabetes mellitus as a polygenic multifactorial disease: immunopathogenic mechanisms of beta-cell destruction. Acta Biomedica, 2005, 76 Suppl 3, 14-8.	0.3	4
146	Italian Addison Network Study: Update of Diagnostic Criteria for the Etiological Classification of Primary Adrenal Insufficiency. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 1598-1604.	3.6	83
147	The role of peripheral benzodiazepine receptors on the function and survival of isolated human pancreatic islets. European Journal of Endocrinology, 2004, 151, 207-214.	3.7	24
148	Improved insulin secretory function and reduced chemotactic properties after tissue culture of islets from type 1 diabetic patients. Diabetes/Metabolism Research and Reviews, 2004, 20, 246-251.	4.0	21
149	Role of caspases in the regulation of apoptotic pancreatic islet beta-cells death. Journal of Cellular Physiology, 2004, 200, 177-200.	4.1	89
150	Pathological changes in human insulitis. Current Opinion in Endocrinology, Diabetes and Obesity, 2004, 11, 82-84.	0.6	0
151	Celiac disease-associated transglutaminase autoantibody target domains at diagnosis are age and sex dependent. Clinical Immunology, 2003, 109, 318-324.	3.2	8
152	NEW-ONSET DIABETES AFTER TRANSPLANTATION: 2003 INTERNATIONAL CONSENSUS GUIDELINES1. Transplantation, 2003, 75, SS3-SS24.	1.0	547
153	Prolonged Exposure to Free Fatty Acids Has Cytostatic and Pro-Apoptotic Effects on Human Pancreatic Islets. Diabetes, 2002, 51, 1437-1442.	0.6	547
154	ICA512(IA-2) Epitope Specific Assays Distinguish Transient from Diabetes Associated Autoantibodies. Journal of Autoimmunity, 2002, 18, 191-196.	6.5	10
155	Neonatal syndromes of polyendocrinopathy. Endocrinology and Metabolism Clinics of North America, 2002, 31, 283-293.	3.2	7
156	Application of phage display peptide library to autoimmune diabetes: identification of IA-2/ICA512bdc dominant autoantigenic epitopes. European Journal of Immunology, 2002, 32, 1420.	2.9	16
157	Upregulation of mitochondrial peripheral benzodiazepine receptor expression by cytokine-induced damage of human pancreatic islets. Journal of Cellular Biochemistry, 2002, 84, 636-644.	2.6	29
158	Upregulation of mitochondrial peripheral benzodiazepine receptor expression by cytokine-induced damage of human pancreatic islets. Journal of Cellular Biochemistry, 2002, 84, 636.	2.6	1
159	Upregulation of mitochondrial peripheral benzodiazepine receptor expression by cytokine-induced damage of human pancreatic islets. Journal of Cellular Biochemistry, 2002, 84, 636-44.	2.6	8
160	BOVINE ISLETS ARE LESS SUSCEPTIBLE THAN HUMAN ISLETS TO DAMAGE BY HUMAN CYTOKINES1. Transplantation, 2001, 71, 21-26.	1.0	25
161	Th2 Cytokines Have a Partial, Direct Protective Effect on the Function and Survival of Isolated Human Islets Exposed to Combined Proinflammatory and Th1 Cytokines. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 4974-4978.	3.6	49
162	Autoantibody negative new onset Type 1 diabetic patients lacking high risk HLA alleles in a Caucasian population: are these Type 1b diabetes cases?. Diabetes/Metabolism Research and Reviews, 2000, 16, 8-14.	4.0	22

#	Article	IF	CITATIONS
163	Effects of prolonged exposure to pancreatic glucagon on the function, antigenicity and survival of isolated human islets. Diabetes/Metabolism Research and Reviews, 2000, 16, 281-286.	4.0	7
164	Function of pancreatic islets isolated from a type 1 diabetic patient. Diabetes Care, 2000, 23, 701-703.	8.6	43
165	Congenital Autoimmune Diabetes Mellitus. New England Journal of Medicine, 2000, 342, 1529-1531.	27.0	15
166	Presence of Interleukin 4 or Interleukin 10, but Not Both Cytokines, in Pancreatic Tissue of Two Patients with Recently Diagnosed Diabetes Mellitus Type I. Autoimmunity, 2000, 32, 161-166.	2.6	6
167	Autoantibody negative new onset Type 1 diabetic patients lacking high risk HLA alleles in a Caucasian population: are these Type 1b diabetes cases?. Diabetes/Metabolism Research and Reviews, 2000, 16, 8-14.	4.0	2
168	Insulin Prophylaxis Down-regulates Islet Antigen Expression and Islet Autoimmunity in the Low-dose Stz Mouse Model of Diabetes. Autoimmunity, 1999, 29, 249-256.	2.6	9
169	T-cell mediated autoimmunity to the insulinoma-associated protein 2 islet tyrosine phosphatase in type 1 diabetes mellitus. European Journal of Endocrinology, 1999, 141, 272-278.	3.7	14
170	Expression of Reg and cytokeratin 20 during ductal cell differentiation and proliferation in a mouse model of autoimmune diabetes. European Journal of Endocrinology, 1999, 141, 644-652.	3.7	44
171	β-cell autoimmunity 1998. , 1998, 14, 1-2.		5
172	The GM2-1 Ganglioside Islet Autoantigen in Insulin-Dependent Diabetes Mellitus Is Expressed in Secretory Granules and Is Notl2 -Cell Specific*. Endocrinology, 1998, 139, 316-319.	2.8	17
173	The GM2-1 Ganglioside Islet Autoantigen in Insulin-Dependent Diabetes Mellitus Is Expressed in Secretory Granules and Is Not Â-Cell Specific. Endocrinology, 1998, 139, 316-319.	2.8	5
174	Autoantibodies to the GM2-1 Islet Ganglioside and to GAD-65 at Type 1 Diabetes Onset. Journal of Autoimmunity, 1997, 10, 585-588.	6.5	21
175	Identification of a novel type 1 diabetes-specific epitope by screening phage libraries with sera from pre-diabetic patients. Journal of Molecular Biology, 1997, 268, 599-606.	4.2	24
176	A new solid-phase radioimmunoassay to detect anti-GAD65 autoantibodies. Journal of Immunological Methods, 1997, 207, 107-113.	1.4	3
177	Gangliosides and autoimmune diabetes. , 1997, 13, 163-179.		37
178	Gangliosides and autoimmune diabetes. Diabetes/metabolism Reviews, 1997, 13, 163-179.	0.3	1
179	Selection of Phage-Displayed Peptides Mimicking Type 1 Diabetes-Specific Epitopes. Journal of Autoimmunity, 1996, 9, 431-436.	6.5	19
180	Antigenic determinants in type 1 diabetes mellitus:. Apmis, 1996, 104, 769-774.	2.0	8

#	Article	IF	CITATIONS
181	Beta-cell markers and autoantigen expression by a human insulinoma cell line: similarities to native beta cells. Journal of Endocrinology, 1996, 150, 113-120.	2.6	21
182	Autoimmunity to the GM2-1 Islet Ganglioside Before and at the Onset of Type I Diabetes. Diabetes, 1996, 45, 1193-1196.	0.6	30
183	Autoimmunity to the GM2-1 islet ganglioside before and at the onset of type I diabetes. Diabetes, 1996, 45, 1193-1196.	0.6	10
184	The Use of Immunological Markers in IDDM After More Than 20 Years From ICA Description. Diabetes/metabolism Reviews, 1996, 12, 121-126.	0.3	1
185	GM2-1 pancreatic islet ganglioside: identification and characterization of a novel islet-specific molecule. Diabetologia, 1995, 38, 1117-1121.	6.3	34
186	Anti-Ganglioside Antibodies in New Onset Type 1 Diabetic Patients and High Risk Subjects. Autoimmunity, 1995, 22, 43-48.	2.6	13
187	GM2-1 pancreatic islet ganglioside: identification and characterization of a novel islet-specific molecule. Diabetologia, 1995, 38, 1117-1121.	6.3	1
188	Autoantigens in type 1 diabetes mellitus. Journal of Endocrinological Investigation, 1994, 17, 497-508.	3.3	2
189	Pancreatic Gangliosides Delay the Onset of Insulitis and Hyperglycaemia in the Low-Dose Streptozotocin Mouse Model. Scandinavian Journal of Immunology, 1993, 37, 308-313.	2.7	1
190	Modulation of antigen expression in relation to intervention strategies in type 1 diabetes. Diabetes/metabolism Reviews, 1993, 9, 245-249.	0.3	6
191	Rat Pancreatic Ganglioside Expression: Differences between a Model of Autoimmune Islet B Cell Destruction and a Normal Strain. Clinical Immunology and Immunopathology, 1993, 66, 143-149.	2.0	16
192	Pancreatic islet ganglioside expression in nonobese diabetic mice: comparison with C57BL/10 mice and changes after autoimmune beta-cell destruction Endocrinology, 1992, 130, 37-42.	2.8	21
193	Autoimmune syndromes in major histocompatibility complex (MHC) congenic strains of nonobese diabetic (NOD) mice. The NOD MHC is dominant for insulitis and cyclophosphamide-induced diabetes Journal of Experimental Medicine, 1992, 176, 67-77.	8.5	162
194	Autoantigens in Thyroid and Islet Autoimmunity: Similarities and Differences. Autoimmunity, 1992, 12, 223-237.	2.6	7
195	Determination of gangliosides by high-performance liquid chromatography with photodiode-array detection. Journal of Chromatography A, 1992, 605, 221-225.	3.7	24
196	Pancreatic islet ganglioside expression in nonobese diabetic mice: comparison with C57BL/10 mice and changes after autoimmune beta-cell destruction. Endocrinology, 1992, 130, 37-42.	2.8	5
197	Type I Diabetes as a "Mendelian―and "Regulated―Immune Process. , 1990, , 351-362.		1
198	Ganglioside Expression in Human Pancreatic Islets. Diabetes, 1989, 38, 1478-1483.	0.6	46

#	Article	IF	CITATIONS
199	Type I diabetes mellitus: A predictable autoimmune disease with interindividual variation in the rate of β cell destruction. Clinical Immunology and Immunopathology, 1989, 50, S85-S95.	2.0	22
200	Ganglioside expression in human pancreatic islets. Diabetes, 1989, 38, 1478-1483.	0.6	10
201	A prozone phenomenon interferes in islet cell antibody detection: Direct comparison of two methods in subjects at risk of diabetes and in insulin dependent diabetics at onset. Journal of Autoimmunity, 1988, 1, 109-117.	6.5	6
202	A Novel Neuroendocrine Cell Surface Glycoprotein: Identification, Isolation, and Initial Characterization*. Endocrinology, 1988, 122, 1263-1268.	2.8	8
203	Circulating Anti-Immunoglobulin Antibodies in Recent-Onset Type I Diabetic Patients. Diabetes, 1988, 37, 462-466.	0.6	15
204	Assay for Cytoplasmic Islet Cell Antibodies Using Two-Color Immunofluorescence and Rat Pancreas. Advances in Experimental Medicine and Biology, 1988, 246, 63-69.	1.6	1
205	Circulating anti-immunoglobulin antibodies in recent-onset type I diabetic patients. Diabetes, 1988, 37, 462-466.	0.6	6
206	Expression of Cytoplasmic Islet Cell Antigens by Rat Pancreas. Diabetes, 1987, 36, 982-985.	0.6	34
207	Humoral and Cellular Immune Abnormalities in Neonates of Diabetic Mothers: Any Pathological Role?. Experimental and Clinical Endocrinology and Diabetes, 1987, 89, 333-339.	1.2	4
208	Immunology in diabetic pregnancy: activated T cells in diabetic mothers and neonates. Diabetologia, 1987, 30, 66-71.	6.3	24
209	Expression of cytoplasmic islet cell antigens by rat pancreas. Diabetes, 1987, 36, 982-985.	0.6	10
210	Activated T cells in normal pregnant women and neonates. European Journal of Obstetrics, Gynecology and Reproductive Biology, 1986, 23, 127-135.	1.1	8
211	The autonomic innervation of the human greater saphenous vein. Acta Histochemica, 1983, 72, 111-116.	1.8	8
212	Micro-RNA expression profiling in Paget's disease of bone. Bone Abstracts, 0, , .	0.0	2
213	Combination of serum miRNA-190 and -95 is a powerful non-invasive tool in the differential diagnosis of thyroid nodules: preliminary data of a prospective series. Endocrine Abstracts, 0, , .	0.0	Ο
214	Clinical and experimental evidence suggest a protective effect of Paget's disease of bone against skeletal metastasization from solid tumors. Bone Abstracts, 0, , .	0.0	0
215	FGF23 and SCL are expressed in carotid plaques and the association between their circulating fractions and fractures differs in relation to comorbidity in elderly individuals. Bone Abstracts, 0, , .	0.0	0
216	FGF23 and SCL are expressed in carotid plaques and the association between their circulating fractions and fractures differs in relation to comorbidity in elderly individuals. Bone Abstracts, 0, , .	0.0	0

#	Article	IF	CITATIONS
217	Selective expresssion of one specific isoform of the coxsackie adenovirus receptor (CAR) in the human pancreatic beta cells. Endocrine Abstracts, 0, , .	0.0	0
218	Outer Membrane Vesicles From The Gut Microbiome Contribute to Tumor Immunity by Eliciting Cross-Reactive T Cells. Frontiers in Oncology, 0, 12, .	2.8	8